Neurocrine Biosciences, Inc. (NBIX)


Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Neurocrine Biosciences, Inc. chart...

About the Company

neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders

CEO

Kevin Gorman

Exchange

NASDAQ

Website

http://www.neurocrine.com/

$71M

Total Revenue

1K

Employees

$14B

Market Capitalization

64.10

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NBIX News

Neurocrine Biosciences Is Pioneering Therapies for Neurological Disorders

3d ago, source:

Neurocrine Biosciences Inc. ( NASDAQ:NBIX) is a pharmaceutical company headquartered in San Diego that specializes in the ...

Decoding 8 Analyst Evaluations For Neurocrine Biosciences

5d ago, source:

Analysts have set 12-month price targets for Neurocrine Biosciences, revealing an average target of $151.88, a high estimate ...

Director Richard Pops Sells Shares of Neurocrine Biosciences Inc (NBIX)

6d ago, source:

Richard Pops, Director of Neurocrine Biosciences Inc (NASDAQ:NBIX), executed a sale of 1,800 shares in the company on March ...

In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences

5d ago, source:

Analysts have recently evaluated Neurocrine Biosciences and provided 12-month price targets. The average target is $151.88, ...

Neurocrine Biosciences Inc's Chief Regulatory Officer Ingrid Delaet Sells 3,000 Shares

3d ago, source: Yahoo Finance

Neurocrine Biosciences Inc (NASDAQ:NBIX), a company specializing in the development of treatments for neurological and ...

Dow Jones Climbs As Donald Trump SPAC Dives; Alphabet Nears Entry Amid Apple Hookup Buzz

9h ago, source: Investor's Business Daily on MSN

The Dow Jones gained on the stock market today. A Donald Trump-linked stock fell while Cathie Wood bought a diving stock. Alphabet neared an entry amid reports of an AI tie-up with Apple.

Boehringer licenses Sosei schizophrenia drugs in €755m deal

7d ago, source: pharmaphorum

Sosei Heptares is a specialist in drugs that target G-protein coupled receptors (GPCRs), a fertile source of drug targets for ...

BeiGene gains as access to leukemia drug Brukinsa expands

5d ago, source: Seeking Alpha

ADRs of BeiGene (NASDAQ:BGNE) traded higher on Wednesday after the company announced that patients in Nepal and Armenia were ...

Voyager Therapeutics: A Tortoise With A Shot At Making Gene Therapy Deliver Easier

10d ago, source:

Voyager Therapeutics investors need to be patient as the biotech targets hard to treat Alzheimer's and Parkinson's. Read why ...

Voyager Therapeutics, Inc.: Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

5d ago, source:

Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment ...

Fate Therapeutics Inc (NASDAQ: FATE) Is Up 85.83 Percent Year-To-Date, But Analysts Anticipate A Price Rally

21d ago, source:

Fate Therapeutics Inc (NASDAQ:FATE) traded at $6.95 at close of the session on Monday, February 26, made a downward move of -0.14% on its previous day’s price. Looking at the stock we see that its ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...